Study Background and Disease Burden
Patients with end-stage kidney disease undergoing maintenance hemodialysis frequently suffer from predialysis hyperkalemia, a condition defined by elevated serum potassium levels, typically 5.5 mmol/l or higher before dialysis sessions. Hyperkalemia is clinically significant due to its strong association with cardiac arrhythmias and increased risk of sudden cardiac death, stroke, and other cardiovascular complications. Managing serum potassium in hemodialysis patients is challenging because of fluctuating potassium levels related to dietary intake, residual kidney function, and dialytic clearance. Sodium zirconium cyclosilicate (SZC) is a novel oral potassium binder with the potential to maintain normokalemia safely and effectively between dialysis sessions. The DIALIZE-Outcomes trial was designed to evaluate whether SZC’s potassium-lowering effect could translate into improved arrhythmia-related cardiovascular outcomes in this vulnerable population, addressing a major unmet medical need.
